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Purpose/Objective: The Young Boost trial, a multicenter 
randomized controlled trial (NCT00212121), investigates 
whether a high boost dose leads to a lower recurrence rate in 
young patients treated with breast conserving therapy, with 
cosmetic outcome as the secondary objective. Here, we 
report the first results on 4 years cosmetic outcome and on 
factors influencing cosmetic outcome. 
Materials and Methods: From 2004-2011, 2421 breast cancer 
patients ≤ 50 yrs were included in The Netherlands, France 
and Germany. All patients were treated with breast 
conserving surgery, followed by whole breast irradiation. 
Patients were randomized to receive a standard low boost 
(n=1211) or a high boost (n=1210) to the tumor bed. The 
boost was delivered either sequentially or simultaneously 
(SIB), to an EQD2 of 50 Gy for the whole breast, 16 Gy for the 
low boost and 26 Gy for the high boost, respectively. 
Cosmetic outcome was scored prior to radiation therapy 
(baseline; BLN), at 1 year and at 4 years follow up (FU) 
according to the following three scoring systems: 
1. BCCT.core: Digital photographs were analyzed using a 
software program to extract an overall cosmetic score: 
excellent, good, fair or poor 
2. Physicians’ opinion: excellent, good, fair or poor 
3. Patients’ satisfactory score using a validated patient’s 
questionnaire: very satisfied, satisfied, not dissatisfied, 
dissatisfied or very dissatisfied 
The scores very satisfied or satisfied and good or excellent 
were grouped as ‘satisfactory’. Score percentages between 
the high and low boost group were compared with an exact 
or χ2.test. For analysis of potential risk factors (tumor 
location, irradiated boost volume, SIB versus sequential 
boost, chemotherapy (yes/no), postoperative complications 
(hematoma/infection/seroma) and seroma separately), the 
change from BLN to 4 yr FU was calculated and compared 
using Wilcoxon or Kruskal-Wallis rank sum tests for 
BCCT.core, assuming this was the most objective scoring 
system.  
Results: Patient characteristics including cosmetic scores 
were similar at BLN for both treatment arms. At 4 yrs, 
cosmetic outcome was significantly better in the low boost 
group than in the high boost group for all three cosmetic 
scores (fig 1): BCCT.core: 67% satisfactory in the low boost 
versus 55% in the high boost group (p=0.0009); physicians: 
63% in the low boost versus 48% in the high boost group 
(p<0.0001); and patients: 62% in the low boost versus 52% in 
the high boost group (p=0.0037).  
Significant risk factors for decline in BCCT.core score from 
BLN were high boost dose (p=0.0008), boost volume > 130 cc 
(p=0.041), chemotherapy (p=0.029) and seroma (p=0.034). 
Tumor location (p=0.39) and SIB versus sequential boost 
(p=0.68) were not significant. 
 
 
Conclusions: These first 4 year results of the Young Boost 
trial show that a high boost results in a worse cosmetic 
outcome. Other risk factors for worse cosmetic outcome are 
boost volume, chemotherapy and seroma.  
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Purpose/Objective: The aim of this prospective study was to 
develop a multivariable prediction model for the risk of 
severe fibrosis in the boost area after breast conserving 
surgery followed by radiotherapy with a simultaneous 
integrated boost (SIB) technique, with a follow-up of 5 years.  
Materials and Methods: The study population was composed 
of 1,030 disease-free patients treated for breast cancer 
(stage 0-III) after breast-conserving surgery, from 2005 to 
2008. The prescribed dose was 50.4 Gy on the whole breast 
with a boost up to 64.4 Gy or 67.2 Gy in 28 fractions. The 
primary endpoint was fibrosis grade II-III in the boost area, 
which was prospectively scored by the physician according to 
the CTCAE criteria v3.0. Univariate and multivariate analyses 
with a bootstrapping method were performed. 
Results: For 546 patients, complete follow-up and dosimetric 
data was available up to five years after treatment. Fibrosis 
grade II-III in the boost area was observed in 13.4% of cases. 
The multivariable analysis resulted in a prediction model with 
three independent variables, including patient age (years), 
percentage of breast volume receiving more than 55 Gy (V55, 
%) and the maximum radiation dose (Dmax, Gy) in the breast. 
The model performed reasonably with regard to 
discrimination (Area under the Curve: 0.66, 95%-CI: 0.59-
0.73) and calibration (Hosmer and Lemeshow test sig. 0.42). 
In this model, the probability of fibrosis in the breast 
increases with increase of Dmax, V55 and age, as shown in 
figure 1. 
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Conclusions: Using this multivariate prediction model a 
reliable prediction of the probability of severe fibrosis in the 
breast can be made. The dose-volume parameters can be 
used to further optimize the radiotherapy planning, in order 
to reduce the incidence of this complication.  
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Purpose/Objective: Accelerated partial breast irradiation 
(APBI) has been studied as an alternative to whole breast 
irradiation for patients with low risk of local recurrence. 
Several studies on postoperative external beam APBI showed 
variable results concerning toxicity and cosmetic outcome. 
Unfavourable results are associated with large treatment 
volumes. Large inter-observer variability in defining the 
tumor bed for postoperative irradiation has been 
demonstrated, resulting in larger irradiated volumes. (1) 
By shifting from postoperative to preoperative radiotherapy 
more accurate target delineation can be performed. (2) 
Furthermore, the breast tissue that received the highest 
radiation dose is surgically removed. As a result, limited 
fibrosis and a good cosmetic outcome is expected. In 
addition, preoperative APBI gives the possibility for 
translational research by assessing tumor response.  
The main objective of Preoperative Accelerated Partial 
Breast Irradiation (PAPBI) trial (ClinicalTrials.gov, 
CT01024582) is to investigate the impact on local control, 
breast fibrosis and cosmesis. In this interim-analysis we 
present the results for the first 70 patients.  
Materials and Methods: In our ongoing phase II, multi-center 
trial women aged ≥ 60 years with an invasive, unifocal ≤ 3 cm 
on MRI, (non-lobular) adenocarcinoma of the breast and a 
negative sentinel node were treated with PAPBI (40 Gy in 10 
fractions over 2 weeks). Six weeks after radiotherapy a wide 
local excision was performed. 
Results: 70 patients with a median follow-up of 21 months 
(3-43 months) were evaluated. Patient characteristics are 
shown in table 1. The mean irradiated (planning target) 
volume was 122 cc (range 13-263).  
The overall postoperative infection rate was 11% and the 
postoperative hematoma rate 5,7%. At 1, 2 and 3 years of 
follow-up no or mild fibrosis was present in respectively 86%, 
97% and 100% of the patients. Fibrosis, when present, was 
only found in a small volume of the breast. The global 
cosmetic outcome scored by the physician was good to 
excellent in 77% at 6 months to 100% at 3 years. (figure 1) 
The majority of the Dutch patients was satisfied to very 
satisfied with the cosmetic result; 81%, 86%, 80% and 79% 
after respectively 0.5,1,2 and 3 years.  
In three patients an ipsilateral tumor recurrence (IBTR) was 
diagnosed; in one patient the IBTR was diagnosed at the skin 
entry of the biopsy tract after 12 months; one patient was 
diagnosed with an IBTR in another quadrant of the breast 
after 26 months; one patient was diagnosed with an IBTR 
after 36 months at the skin entry of the biopsy tract. 
 
 
Table 1: patient characteristics 
 
 
Conclusions: The first results of the PAPBI trial show low 
complication rates, limited fibrosis in a small volume and 
good to excellent cosmetic outcome. Fibrosis of the breast 
and cosmetic outcome scored by the physician improve over 
time. In three patients an IBTR was diagnosed. In selected 
